Corbus Pharmaceuticals

CRBP

Market cap $142M

Overview Fund Activity

11.62 USD

+1.35

13.15%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

11.26

-0.36

3.1%

1 day

13.15%

5 days

21.17%

1 month

25.62%

3 months

40.34%

6 months

66.95%

Year to date

-3.49%

1 year

-77.17%

5 years

-80.24%

10 years

-81.38%

About: Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Employees: 28

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

13% more capital invested

Capital invested by funds: $55.4M [Q1] → $62.5M (+$7.13M) [Q2]

8% less funds holding

Funds holding: 86 [Q1] → 79 (-7) [Q2]

11.23% less ownership

Funds ownership: 85.29% [Q1] → 74.06% (-11.23%) [Q2]

14% less call options, than puts

Call options by funds: $138K | Put options by funds: $161K

33% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 21

41% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 29

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$40

244% upside

Avg. target

$47

300% upside

High target

$53

356% upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Andres Y. Maldonado	$40	Buy Reiterated	17 Sep 2025
Oppenheimer Jeff Jones	$53	Outperform Maintained	6 Aug 2025

See Analyst Rankings

Financial journalist opinion

FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma

NORWOOD, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage oncology and obesity company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CRB-701 for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) previously treated with platinum-based chemotherapy and an anti-PD(L)-1 therapy. A Fast Track designation for relapsed or refractory metastatic cervical cancer was granted by the FDA in December 2024.

FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma

The Motley Fool

Corbus (CRBP) Q2 Loss Beats Estimates

Corbus (CRBP) Q2 Loss Beats Estimates

Corbus (CRBP) Q2 Loss Beats Estimates

Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

NORWOOD, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on oncology and obesity, today announced the dosing of the first participant in the PD-1 combination arm of its Phase 1 study investigating CRB-701 in solid tumors (the Phase 1 Western study). Participants in this arm of the study are being randomized to the 2.7 mg/kg and 3.6 mg/kg cohorts in combination with Keytruda® (pembrolizumab).

Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium

NORWOOD, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fire side chat at the Piper Sandler 3rd Annual Virtual Obesity Symposium, to be held on June 26, 2025. The event will include presentations by key opinion leaders and fireside chats with companies developing obesity therapeutics. Piper Sandler clients can register for the event through their representative.

Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium

Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data?

CRBP's pipeline shows promise, especially CRB-701 with early signals of benefit and tolerability, but all programs remain in early clinical stages. The company's financial position is stable for now, with about two years of cash runway, but rising R&D costs could accelerate the need for funding. Market sentiment has become overly negative, valuing the pipeline at essentially zero after a steep drop unrelated to CRBP's own data.

Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data?

Zacks Investment Research

3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies

NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.

3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies

Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

NORWOOD, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference, to be held June 3-5, 2025 in New York, NY.

Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15.

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

Zacks Investment Research

Is Small-Cap Corbus Pharma a Worthy Cannabis Investment?

While CRBP's pipeline shows promise, the company's lack of marketed products remains a concern.

Is Small-Cap Corbus Pharma a Worthy Cannabis Investment?

Zacks Investment Research

3 Unconventional Cannabis Stocks to Watch in 2025

Think cannabis investing is all hype? These three unconventional stocks could change your mind - and your portfolio - in 2025.

3 Unconventional Cannabis Stocks to Watch in 2025

See News Rankings

Charts implemented using Lightweight Charts™